Incyte approved by FDA for special PV protocol
September 2010
The FDA has approved a special protocol for Incyte's clinical trial for Polycythemia Vera patients. Their RESPONSE (Randomized, open label, multicenter phase III study of Efficacy and Safety in POlycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst available care) is expected to enroll approximately 300 patients worldwide who are resistent to hydroxyurea.
For the full article click here
